Tests a CAR T cell therapy, KYV-101, in adults with generalized myasthenia gravis
Compares KYV-101, a cell therapy, with standard treatment in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Key facts
- Where
- Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, and Munich, GermanySee the 7 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06193889, who can take part
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- St. Josef HospitalBochum, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Universitaetsklinikum Jena KöRJena, GermanyTaking people
- Universitaetsklinikum Magdeburg AöRMagdeburg, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kyverna Therapeutics
- Trial code
- NCT06193889EU 2023-509892-17-00
- Record updated
- 29 July 2026
- Original description
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia GravisRead full original descriptionShow less
KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Inclusion: Presence of autoantibodies to AChR or MuSK; Myasthenia Gravis Foundation of America (MGFA) Class II-IV; MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit; QMG total score of ≥11 at screening an confirmed at baseline visit; Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms; On a stable dose of glucocorticoids and/or other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required; No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening; No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen); No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening; Able and willing to attend the necessary visits to the study site.
Exclusion: Unable to washout or interrupt autoimmune disease therapy prior to apheresis and/or baseline if required; Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target; Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures; Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy); History of stroke (with residual sequalae and/or risk for recurrence), seizure (even if well controlled on antiepileptics), neurodegenerative disease, altered mental status (unexplained and/or recent/current), or uncontrolled/severe psychiatric disease; Any serious and/or uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, clinically significant cardiac or pulmonary disease; History of primary immunodeficiency, organ or allogeneic bone marrow transplant, or splenectomy; Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections; Thymectomy <12 months of screening or planned during the study.